TGF beta Activation

Advances in Transforming Growth Factor-β Signaling

Retrieved on:

Wednesday, February 17, 2021

Branches of biology, Proteins, Protein structure, Signal transduction, Transforming growth factor beta, TGF beta receptors, Transforming growth factor, Cytokine, Activin and inhibin, TGF beta Activation, TGF beta signaling pathway

Transforming growth factor beta (TGF-) is a multifunctional cytokine produced in all white blood cells lineages.

Key Points:

Transforming growth factor beta (TGF-) is a multifunctional cytokine produced in all white blood cells lineages.
Thompson said "This study helps bring into focus how antagonists of the TGF-family are positioned on the cell surface and how this could potentially impact signaling.
The binding of follistatin and heparin unexpectedly impaired the association of mysostatin and activin A which are ligands of the TGF-family.
Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences.

TGF Beta Receptor Type 1 - 2020 Pipeline Review, H1 - ResearchAndMarkets.com

Retrieved on:

Friday, April 3, 2020

Health, Pharmaceutical, Branches of biology, Proteins, Transforming growth factor beta, Health sciences, Mechanism of action, Transcription factors, Signal transduction, SMAD, TGF beta Activation

The "TGF Beta Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

The "TGF Beta Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
TGF Beta Receptor Type 1 pipeline Target constitutes close to 17 molecules.
This report outlays comprehensive information on the TGF Beta Receptor Type 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Furthermore, this report also reviews key players involved in TGF Beta Receptor Type 1 targeted therapeutics development with respective active and dormant or discontinued projects.

Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor: Well Tolerated, Target Inhibition Demonstrated at All Dose Levels, Data Reported at SITC

Retrieved on:

Friday, November 8, 2019

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Proteins, Transforming growth factor beta, Cell biology, TGF beta 1, Transcription factors, Growth factors, Signal transduction, TGF beta Activation, SMAD, TGF-beta 1 & 3, Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer

AVID200 is a first-in-class, selective inhibitor of TGF-beta 1 & 3, the main pathogenic TGF-beta isoforms.

Key Points:

AVID200 is a first-in-class, selective inhibitor of TGF-beta 1 & 3, the main pathogenic TGF-beta isoforms.
AVID200 achieved dose-proportional exposure and exhibited peripheral target inhibition of TGF-beta 1 & 3 over the entire dosing period at all dose levels tested.
Several patients experienced stable disease including one patient with prolonged stable disease of more than 8 months who continues on treatment.
Forbius lead TGF-beta 1 & 3 inhibitor, AVID200, is undergoing Phase 1 clinical trials in two fibrotic indications as well as in solid tumors.

Forbius: Phase 2 Clinical Data with Tumor-Selective Anti-EGFR ADC AVID100 Featured at AACR-NCI-EORTC and World ADC San Diego

Retrieved on:

Thursday, October 10, 2019

We are focused on the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.

Key Points:

We are focused on the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.
Forbius team of TGF-beta biology experts designed a proprietary platform of TGF-beta inhibitors with best-in-class potency and selectivity against the principal disease-driving isoforms 1 & 3.
Forbius lead TGF-beta 1 & 3 inhibitor, AVID200, is undergoing Phase 1 clinical trials in two fibrotic indications as well as in solid tumors.
AVID100 is an anti-EGFR antibody-drug conjugate (ADC) with a novel tumor-selective mode of action.

ESMO 2019: Forbius Demonstrates Target Engagement in Phase 1 Immuno-Oncology Clinical Trial with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor

Retrieved on:

Saturday, September 28, 2019

Research, Oncology, Other Education, Education, Science, Clinical trials, Biotechnology, Other Science, Health, Branches of biology, Transforming growth factor beta, Biology, TGF beta Activation, Epithelial–mesenchymal transition, TGF-beta 1 & 3, Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer

AVID200 is an isoform-selective and highly potent inhibitor of TGF-beta 1 & 3 undergoing Phase 1 clinical testing in solid tumors and fibrotic diseases.

Key Points:

AVID200 is an isoform-selective and highly potent inhibitor of TGF-beta 1 & 3 undergoing Phase 1 clinical testing in solid tumors and fibrotic diseases.
TGF-beta 1 & 3 are the principal disease-driving isoforms, while TGF-beta 2 is responsible for normal cardiac function and hematopoiesis.
Therefore, AVID200 is positioned to be an effective and well-tolerated therapeutic in a variety of clinical settings, including in combination with anti-PD-(L)1 therapy.
Forbius lead TGF-beta 1 & 3 inhibitor, AVID200, is undergoing Phase 1 clinical trials in two fibrotic indications as well as in solid tumors.

Forbius to Present at Jefferies 2019 Healthcare Conference

Retrieved on:

Tuesday, June 4, 2019

Health, Biotechnology, Oncology, Research, Science, Branches of biology, Signal transduction, Cell signaling, Cell biology, Growth factors, Epidermal growth factor receptor, Oncogenes, Transforming growth factor beta, Transforming growth factor, Endoglin, Transcription factors, TGF beta Activation

Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, announced today that Ilia Tikhomirov, CEO of Forbius, will be presenting a company overview at the Jefferies 2019 Healthcare Conference in New York City held June 4-7, 2019.

Key Points:

Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, announced today that Ilia Tikhomirov, CEO of Forbius, will be presenting a company overview at the Jefferies 2019 Healthcare Conference in New York City held June 4-7, 2019.
Details of the presentation are as follows:
Forbius is a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer.
We are focused on the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.
Forbius team of TGF-beta biology experts designed a proprietary platform of TGF-beta inhibitors withbest-in-class potency andselectivity against the principaldisease-driving isoforms 1 & 3.

Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

Retrieved on:

Tuesday, March 5, 2019

Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Branches of biology, Medicine, Proteins, Transforming growth factor beta, Clinical medicine, TGF beta 1, Fibrosis, Scleroderma, TGF beta Activation

, Professor of Medicine, Medsger Professor and Director of the Scleroderma Center at the University of Pittsburgh Medical Center.

Key Points:

, Professor of Medicine, Medsger Professor and Director of the Scleroderma Center at the University of Pittsburgh Medical Center.
AVID200 selectively neutralizes TGF-beta 1 & 3 with best-in-class pM potency, thus simultaneously neutralizing the principal pro-fibrotic TGF-beta isoforms and providing optimal efficacy.
For decades, safe and potent neutralization of TGF-beta has been the holy grail for the treatment of fibrotic diseases.
AVID200 is a rationally designed, highly potent TGF-beta 1 & 3 inhibitor undergoing Phase 1 clinical testing in fibrosis and solid tumors.